A new population-level study from Uppsala University has found that most men treated for non-metastatic prostate cancer according to current clinical guidelines have a favorable long-term prognosis.

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

A local cancer survivor, Robert Dames, has released a new book titled "Cancer - What Now" to assist others in navigating the ...

Bob Lane discusses his experience with prostate cancer, and describes what survivorship and cure means to him as someone ...

ArteraAI Prostate analyzes digital pathology images of a prostate cancer biopsy slide to help clinicians predict long-term outcomes.

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

The National Cancer Institute faces severe budget cuts, staff exodus, and halted research, threatening decades of progress ...

Researchers investigated how Mindfulness-Based Cancer Recovery and Tai Chi/Qijong interventions could reduce distress levels in cancer survivors.